Xiaohong Yan Selected Research

verinurad

11/2019	Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
1/2018	Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
1/2018	Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.
1/2018	Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaohong Yan Research Topics

Disease

23	Neoplasms (Cancer) 10/2022 - 09/2005
11	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 06/2011
4	Wounds and Injuries (Trauma) 02/2022 - 06/2012
4	Neoplasm Metastasis (Metastasis) 01/2021 - 05/2012
4	Hypoxia (Hypoxemia) 01/2020 - 08/2008
4	Gout 11/2019 - 01/2018
3	Inflammation (Inflammations) 02/2022 - 01/2006
3	Residual Neoplasm 02/2022 - 07/2011
3	Urinary Incontinence 01/2017 - 06/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 01/2022
2	Overweight 10/2022 - 01/2021
2	Endometriosis 12/2020 - 08/2020
2	Infertility (Sterility) 12/2020 - 08/2020
2	Overactive Urinary Bladder (Overactive Bladder) 01/2017 - 06/2013
2	Infections 12/2008 - 02/2008
1	Obesity 10/2022
1	Abdominal Obesity 10/2022
1	Dementia (Dementias) 03/2022
1	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 01/2022
1	Testicular Neoplasms (Testicular Cancer) 03/2021
1	Insulin Resistance 01/2021
1	Hemorrhage 01/2020
1	Atherosclerosis 01/2020
1	Hyperuricemia 11/2019
1	Lung Neoplasms (Lung Cancer) 01/2019
1	Osteosarcoma (Osteogenic Sarcoma) 11/2017
1	Flatulence 10/2017
1	Hypothermia 10/2017
1	Pain (Aches) 10/2017
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2017

Drug/Important Bio-Agent (IBA)

10	Proteins (Proteins, Gene)FDA Link 02/2022 - 12/2008
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2022 - 10/2010
4	verinuradIBA 11/2019 - 01/2018
3	Insulin (Novolin)FDA Link 10/2022 - 01/2021
3	Type A Botulinum Toxins (Botox)FDA Link 01/2017 - 06/2013
2	adagrasibIBA 10/2022 - 01/2022
2	Angiopoietin-2IBA 02/2022 - 06/2012
2	IntegrinsIBA 02/2022 - 09/2005
2	Biological ProductsIBA 01/2022 - 01/2019
2	Messenger RNA (mRNA)IBA 01/2022 - 03/2021
2	IodineIBA 04/2021 - 01/2021
2	RNA (Ribonucleic Acid)IBA 03/2021 - 08/2020
2	AntigensIBA 03/2021 - 11/2017
2	MicroRNAs (MicroRNA)IBA 08/2020 - 11/2017
2	Pharmaceutical PreparationsIBA 01/2020 - 07/2012
2	Uric Acid (Urate)IBA 01/2018 - 01/2018
2	Febuxostat FDA Link 01/2018 - 01/2018
2	Cholinergic Antagonists (Anticholinergics)IBA 01/2017 - 06/2013
1	sitravatinibIBA 10/2022
1	CholesterolIBA 10/2022
1	c-Mer Tyrosine KinaseIBA 10/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2022
1	Phosphotransferases (Kinase)IBA 10/2022
1	oxidized low density lipoproteinIBA 10/2022
1	Triglycerides (Triacylglycerol)IBA 10/2022
1	Hormones (Hormone)IBA 10/2022
1	AcidsIBA 03/2022
1	Proton Pump InhibitorsIBA 03/2022
1	Glycoproteins (Glycoprotein)IBA 02/2022
1	OsteopontinIBA 02/2022
1	Plasminogen Activators (Plasminogen Activator)IBA 02/2022
1	Plasminogen Activator Inhibitor 1IBA 02/2022
1	SolutionsIBA 01/2022
1	Long Noncoding RNAIBA 01/2022
1	PlatinumIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	EnzymesIBA 08/2021
1	AntibodiesIBA 03/2021
1	CalciumIBA 03/2021
1	Tyrosine (L-Tyrosine)FDA Link 03/2021
1	VaccinesIBA 03/2021
1	Complementary DNA (cDNA)IBA 03/2021
1	Protein Isoforms (Isoforms)IBA 03/2021
1	Blood Glucose (Blood Sugar)IBA 01/2021
1	Fibroblast Growth Factor 7 FDA Link 01/2021
1	Circular RNAIBA 12/2020
1	Angiotensin IIIBA 01/2020
1	isoliquiritigenin (GU 17)IBA 01/2020
1	Therapeutic UsesIBA 01/2020
1	Apolipoproteins E (ApoE)IBA 01/2020
1	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 01/2020
1	ApolipoproteinsIBA 01/2020
1	Allopurinol (Remid)FDA LinkGeneric 01/2018
1	Interleukin-8 (Interleukin 8)IBA 01/2018
1	BenzbromaroneIBA 01/2018
1	ChromatinIBA 11/2017
1	Narcotics (Narcotic Analgesics)IBA 10/2017
1	KetorolacIBA 10/2017
1	Interleukin-6 (Interleukin 6)IBA 10/2017

Therapy/Procedure

4	Therapeutics 01/2022 - 02/2008
2	Injections 01/2022 - 01/2012
1	Drug Therapy (Chemotherapy) 01/2022
1	Immunotherapy 03/2021
1	Splenectomy 01/2020
1	Precision Medicine 01/2020
1	Length of Stay 10/2017
1	Minimally Invasive Surgical Procedures 10/2017
1	Analgesia 10/2017
1	Proctectomy 01/2017
1	Operative Time 01/2017